Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.06.19
Views: 868

Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands

Dr Martijn Lolkema talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the selective inhibitor OMO-1 and its effect in patients with c-MET aberrations which are found in lung cancer.

He describes the mechanism, tolerability and safety of this drug in c-Met driven cancers, which was found to target these mutations effectively.

Dr Lolkema discusses the next steps for this study, which include expanding the patient cohort and combining this drug with other types of therapies.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation